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Purpose: This report describes the authors’ initial experience with the Excluder thoracic endoprosthesis (W. L. Gore and
Associates, Inc, Flagstaff, Ariz) and the thoracic Talent endoprosthesis (Medtronic AVE, Sunrise, Fla) and their safety
and efficacy in the primary endovascular repair of descending thoracic aortic aneurysms (TAAs). In addition, comparison
with a historic nonrandomized cohort of patients that had undergone open repair of descending TAAs is reported.
Patients and methods: Repair of TAA (mean diameter, 68 22 mm) was attempted in 19 patients with the Excluder (n
14) and the Talent (n  5) endoprostheses between March 1999 and January 2000. This group was compared with a
historic nonrandomized cohort of 10 patients that had undergone open repair of anatomically similar descending TAA
(mean diameter, 74  22 mm) between January 1996 and January 1998. The mean age in the endovascular group was
70.6  5.3 years versus 70.1  4.5 years in the historic open group. All the procedures were performed in a standard
operating room with angiographic capabilities. In the historic open group, each standard tube graft repair of descending
TAA was performed by one of three staff surgeons.
Results: Endograft deployment was successful in 18 patients (95%). The procedure was aborted in one patient (Excluder)
because of small iliac arteries and access difficulty. The average operative time was 155  62 minutes, with a mean blood
loss of 325 353 mL (versus 256 102 minutes and 1205 1493 mL, respectively, in the open group). Eight patients
needed the planned use of more than one component for enhanced sealing or additional length in the endovascular group.
No type I endoleaks were identified on the intraoperative completion angiography. One perioperative mortality occurred
in the endovascular group and the open group. In the endovascular group, other complications included retroperitoneal
hematoma and external iliac artery dissection (n  1), lymphocele (n  1), and common femoral artery pseudoaneurysm
(n  1). In the open group, other complications included ischemic colitis (n  1), severe renal insufficiency (n  2),
wound infection (n  1), and stroke (n  1). In the endovascular group, the length of stay was 6.2  3.3 days (range, 1
to 13 days), with only nine patients needing intensive care, whereas in the open group, the length of stay was 16.3  6.7
days, with all patients needing intensive care. Endoleaks, graft migrations, or ruptures were not seen on the 1-month,
6-month, and 12-month follow-up computed tomographic scans in the endovascular group. On the average, aneurysm
size decreased from 68  22 mm to 58  13 mm, to 51  14 mm, and to 49  12 mm at 1, 6, and 12 months after
endovascular repair, respectively. No spinal cord ischemia was seen in either group.
Conclusion: The endoluminal repair was effective in exclusion of descending TAAs from the systemic circulation in this
selected group of patients. In this short-term follow-up, compared with the nonrandomized historic cohort of open
descending TAA repair, the endovascular group had significantly shorter operating times and hospital and intensive care
unit stays and lower operative blood loss. Further follow-up and continued assessment of the long-term durability of
these devices in elective and emergency circumstances are warranted. (J Vasc Surg 2002;36:732-7.)
The standard treatment for descending thoracic aortic
aneurysm (TAA) is open graft interposition.1,2 Since the
first endovascular treatment of abdominal aortic aneurysm
by Parodi, Palmaz, and Barone3 in 1991 and the first
description of endovascular repair of a descending TAA by
Volodos and his coworkers4 in 1991, many studies have
shown the technical feasibility and effectiveness for aortic
aneurysm exclusion from the systemic circulation with an
endoluminal stent graft system.5-9 Various anatomic fea-
tures of TAAs exclude many patients from endoluminal
repair or lead to technical difficulties in stent graft delivery.
Anatomic limitations for the applicability of thoracic stent
grafts include short or wide proximal or distal landing
zones, severe neck angulation, and tortuous or stenotic
access arteries. The criteria for candidate selection are
evolving, as is the development of improved grafts and
delivery systems. As experience with stent grafts and en-
doluminal techniques increases along with refinement of
devices, more patients with descending TAAs likely will be
treatable in this manner.
The Excluder (W. L. Gore and Associates, Inc, Flag-
staff, Ariz) and Talent (Medtronic AVE, Sunrise, Fla) en-
doprostheses are devices that are under clinical investiga-
tion in the United States and allow for the primary
endovascular treatment of selected descending TAAs. The
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initial feasibility (phase I) study for the Excluder thoracic
endoprosthesis was conducted in the United States with
two investigational centers enrolling 28 patients. The initial
feasibility (phase I) study for the Talent endoprosthesis was
conducted in the United States with five investigational
sites enrolling 22 patients. Complications related to pros-
thesis deployment did not occur, nor were there any acute
conversions to open aneurysm repair. Our institution has
been involved in the multicenter, manufacturer-sponsored,
US Food and Drug Administration–approved phase II trial
of the Excluder thoracic endoprosthesis. In addition, the
Talent endograft was used in five cases on a compassionate
basis. Herein, we detail our initial results with the Excluder
and the Talent endoprostheses for endoluminal repair of
descending TAAs.
PATIENTS AND METHODS
Patient selection. Between March 1999 and January
2000, 12 eligible patients (of 16 patients screened) were
part of an US Food and Drug Administration phase II
multicenter trial with the Excluder thoracic endoprosthesis.
In addition, two additional patients were treated with the
Excluder device and five patients were treated with the
Talent device on the compassionate use basis because they
did not satisfy one or more of the criteria for inclusion as set
forth by the respective trial protocols. To date, in our
institution, the endovascular procedure was attempted in
19 patients (four women and 15 men) with an average age
of 70.6  5.3 years (range, 59 to 78 years).
A historic nonrandomized cohort of patients (mean
age, 70.1 4.5 years; range, 67 to 75 years) with descend-
ing TAA (mean diameter, 74  22 mm) who had under-
gone open repair between 1996 and 1998 and who would
have been candidates for endoluminal repair on the basis of
anatomic criteria was identified. During the open proce-
dures, retrograde perfusion of the mesenteric and renal
arteries was maintained via a left atrium to left femoral
bypass with the use of a Biomedicus pump (n  3) (Bio-
medicus, Eden Prairie, Minn) or a temporary right axillary-
femoral bypass (n  7). Risk factor profiles (Table I) and
TAA characteristics (Table II) and operative and postoper-
ative outcome data for the endoluminal and historic non-
randomized open groups were collected with review of
medical records (Table III).
The phase II protocol required that all patients have
acceptable medical risk profiles for open aneurysm repair if
surgical conversion were to become necessary. After study
inclusion/exclusion criteria were met, the risks and benefits
of stent graft placement were fully explained to each patient
and they were given the choice of open surgical repair or
endoluminal therapy of TAA. All patients provided in-
formed consent, and the institutional review board at
Emory University Hospital approved the prospective study
protocol.
The study protocol included patients with a descending
TAA of more than two times the diameter of the adjacent
aorta or a saccular aneurysm with a thrombus-free nonan-
eurysmal proximal aortic landing zone of more than 20 mm
Table I. Patient characteristics and operative risk factors
Characteristic Open repair Endoluminal repair
Age (mean  SD; y) 70.1  4.5 70.6  5.3
Gender
Male 3 (30%) 15 (79%)
Female 7 (70%) 4 (21%)
Coronary artery disease 5 (50%) 11 (58%)
Coronary revascularization* 4 (40%) 6 (32%)
Previous acute myocardial infarction 3 (30%) 1 (5%)
Peripheral vascular disease 2 (20%) 7 (37%)
Congestive heart failure 2 (20%) 7 (37%)
Hypertension 9 (90%) 17 (89%)
Renal insufficiency†
Mild 1 (10%) 4 (21%)
Severe 0 0
*Either coronary artery bypass grafting or percutaneous transluminal coronary angioplasty.
†Mild renal insufficiency defined as creatinine level 1.3 to 2.0 mg/dL. Severe renal insufficiency defined as creatinine level 2.0 mg/dL.
SD, Standard deviation.
Table II. Preoperative descending TAA characteristics
Open repair group
(mean  SD; range)
Endoluminal repair group
(mean  SD; range) P value
Maximum aneurysm diameter (mm) 73  22 (40-110) 68  21 (32-150) .6
Aneurysm length (mm) 81  43 (55-190) 77  60 (10-250) .9
Proximal landing zone length (mm) N/A 56  30 (20-100)
Proximal landing zone diameter (mm) N/A 33  4 (26-38)
SD, Standard deviation; N/A, not applicable.
JOURNAL OF VASCULAR SURGERY
Volume 36, Number 4 Najibi et al 733
in length and with angulation of the aortic segment of less
than 60 degrees. The iliofemoral system had to be able to
accommodate the 22F to 27F introducer sheath (ie, outer
diameter, 22F to 27F, equal to vessel diameter of 7.3 to 8.9
mm). Patients were excluded from the protocol if they had
a recent myocardial infarction or stroke (6 weeks), pul-
monary insufficiency necessitating chronic home oxygen
therapy, or renal insufficiency (creatinine level, 2.0 mg/
dL). No other surgical procedures could take place at the
same time or within 30 days before endograft placement,
except left carotid to subclavian bypass (to obtain a more
proximal landing zone).
The patients who underwent treatment with the en-
doluminal approach on the compassionate basis did not
satisfy one or more of the criteria for inclusion set forth by
the trial protocol. These criteria included pulmonary insuf-
ficiency necessitating chronic home oxygen therapy, con-
tained rupture, and status as not being an open operative
candidate. These patients also provided informed consent,
and the institutional review board at Emory University
Hospital approved the procedures.
Preprocedural screening. All patients in the en-
dograft group underwent thoracic, abdominal, and pelvic
computed tomographic scanning with 3-mm collimation
and contrast enhancement from the ascending aorta to the
common femoral arteries. The proximal aortic landing
zone diameter could not be greater than 37 mm for the
Excluder and 46 mm for the Talent because of sizing
constraints. With a calibrated pigtail catheter (Cook, Inc,
Bloomington, Ind), an aortography was performed to eval-
uate the dimensions, patency, and tortuosity of the arch
vessels, the thoracic aorta, and its branches and access
vessels (femoral and iliac arteries). All studies were per-
formed within the 6 months before implantation per pro-
tocol.
Endograft group aortic anatomy. The average aneu-
rysm diameter was 68  22 mm (range, 47 to 130 mm).
This group included one patient with a contained rupture
of the descending TAA. The mean total length of the
involved aorta was 77  60 mm (range, 32 to 250 mm).
The mean length and diameter of the proximal landing
zone were 56  30 mm (range, 25 to 100 mm) and 33 
4 mm (range, 26 to 37 mm), respectively. The left common
iliac artery diameter measured 11  2 mm (range, 6 to 14
mm). Similarly, the right common iliac diameter was 12 
6 mm (range, 8 to 30 mm). All diameter measurements
were performed with internal vessel diameters. Four pa-
tients (21%) had one or more iliac arteries measuring less
than 1 cm in diameter. Unilateral common iliac aneurysms
were present in two patients with two aneurysms extending
to the iliac bifurcation.
Historic open group aortic anatomy. The average
aneurysm length and diameter were 81  43 mm (range,
37 to 185 mm) and 73  22 mm (range, 40 to 110 mm),
respectively. This group included one patient with con-
tained rupture and two symptomatic pseudoaneurysms.
Technical aspects: Endovascular. The Excluder tho-
racic endoprosthesis is a modular system manufactured
with an expanded polytetrafluouroethylene prosthesis and
is supported with a self-expanding nitinol stent exoskeleton
structure. Each device component has an attached sleeve
made of expanded polytetrafluoroethylene that is sewn
closed around the prosthesis and functions to constrain it
during positioning.
The self-expanding components of the Excluder tho-
racic endoprosthesis are preloaded on delivery catheters
that are similar for various component sizes. The endopros-
thesis components are packaged in 20F to 24F delivery
catheters, depending on the endograft diameter.
The thoracic Talent endoprosthesis is a self-expanding
endograft consisting of a polyester graft fabric and a self-
expanding nitinol exoskeleton. The device components are
packaged in 24F to 27F delivery catheters, depending on
the endograft diameter.
The procedures were performed in a standard operat-
ing room with angiographic capability by a team of vascular
surgeons and interventional radiologists. General anesthe-
sia was used in all patients. Each patient received prophy-
lactic perioperative antibiotics and systemic heparin (100
units/kg) during the procedure. The common femoral and
iliac arteries were used as access sites in 15 and four patients,
respectively. With a calibrated angiographic catheter with
1-cm radiopaque markings (Cook, Inc) placed in the as-
cending aorta through the left brachial access port, an
arteriogram first was performed to verify TAA dimensions
and to determine the positioning of the device. Fluoro-
scopic guidance (OEC 9600, OEC Medical Systems, Inc,
Thousand Oaks, Calif) was used for placement of the
endograft. Before deployment, correct position according
to the location of radiopaque markers was ensured. With
Table III. Patient operative and postoperative outcomes
Characteristic Open repair (n  10) Endoluminal repair (n  19) P value
Estimated blood loss (mL) 1205  1493 325  353 .01†
Operative time (min) 255  101 155  62 .01†
Patients with mild renal insufficiency* 3 (30%) 3 (16%) .6
Patients with severe renal insufficiency* 1 (10%) 2 (11%) 1.0
ICU stay (d) 11  12 0.8  1.0 .03†
Hospital stay (d) 16  7 6  3 .002†
*On basis of creatinine level on day before discharge (mild, creatinine level 1.50 to 2.29 mg/dL; severe, creatinine level 2.30 mg/dL).
†Statistical significance defined as P  .05.
ICU, Intensive care unit.
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the pigtail catheter positioned in the ascending aorta
(through the left brachial access), a completion angiogram
was obtained with prolonged digital subtraction angiogra-
phy for detection of the presence of an endoleak.
Technical aspects: Open aneurysm repair. The his-
toric cohort of open repair had undergone operative repairs
for aneurysms that were symptomatic, more than two times
the diameter of the adjacent normal aorta, or more than 6
cm in diameter. Open surgical repair was performed with
standard tube graft interposition electively in seven patients
and emergently in three patients.
In the endovascular group, the 30-day technical success
rate was defined on an intent-to-treat basis as successful
endograft deployment without death, need for standard
open aortic reconstruction for 30 days, or evidence of
persistent (48 hours) endoleak. Clinical success rate was
inclusive of those patients who at 6 months after implanta-
tion had spontaneous seal of a persistent endoleak and
showed no evidence of aneurysm enlargement. Other out-
comes analyzed included successful graft deployment, irre-
spective of the presence or absence of endoleak, surgical
time, operative blood loss, duration of stay in an intensive
care unit, length of hospital stay, and patient morbidity and
mortality. Computed tomographic scans were performed at
1, 6, and 12 months for assessment of complete exclusion
of the TAA.
Statistical analysis were performed with the unpaired t
test and analysis of variance with the InStat computer
program (Intuitive Software for Science, San Diego, Calif).
RESULTS
Total operative time averaged 156  63 minutes (ver-
sus 256 102 minutes in the open group), blood loss was
325  353 mL (versus 1205  1493 mL in the open
group), and the amount of intravascular contrast was
236  110 mL. Patients had an average of 6.2  5.8
postoperative hospital days (versus 16.3  6.7 days in the
open group), with 0.8  1.0 days in an intensive care unit
(versus 11  12 days in the open group).
Technical and clinical success. Endovascular stent
graft deployment was successful in 18 of the 19 patients
who underwent the procedure (technical success rate,
95%). No intraoperative open conversions or deaths oc-
curred. The 30-day technical success rate on an intent-to-
treat basis, as defined by the Society for Vascular Surgery/
International Society for Cardiovascular Surgery reporting
standards, was 89% (17/19). On completion angiography,
no type I endoleaks were observed. At the first, second, and
third scheduled computed tomographic scans (at 1-month,
6-month, and 12-month follow-up visits), no endoleaks
were discovered.
Patient outcomes. A mean follow-up period of 12
months (range, 3 to 22 months) has been completed on the
patients who underwent implantation. One patient had a
preoperative contained rupture and, despite successful en-
doluminal exclusion of the aneurysm, died of severe adult
respiratory distress syndrome and unresponsive hypoxia on
postoperative day 2. Another patient died suddenly 5
months after hospital discharge; a computed tomographic
scan 4 weeks before the death had not shown presence of
endoleak or any evidence of aneurysm enlargement. Post-
mortem studies were refused in both cases, and therefore, a
conclusion for the causes of death is not possible. These
two cases have been considered as clinical failures in our
data analysis. Thus, the clinical success rate at 12 months
was 84% (of 16 living patients).
The total morbidity rate in the endograft group was
26%. Major and minor morbidities occurred in four pa-
tients (21%) and one patient (5%), respectively. One patient
had a retroperitoneal hematoma and external iliac artery
dissection after implantation. This patient was treated with
evacuation of hematoma and an iliofemoral bypass and
discharged home on day 14. Another patient had a com-
mon femoral artery pseudoaneurysm develop that was ad-
dressed surgically on postoperative day 2. Two patients had
creatinine levels of more than 2.3 mg/dL on the day before
discharge but did not need dialysis. In addition, one minor
morbidity consisted of inguinal lymphocele. This was suc-
cessfully treated surgically, and the patient was discharged
on postoperative day 5.
During the follow-up period, we have observed no late
endoleak development or stent graft migration. However,
at 22 months of follow-up, one case of stent fracture with
continued reduction in aneurysmal diameter and no en-
doleak was been identified on plane radiograph (Excluder).
Furthermore, no aneurysm enlargement has been seen
during this short-term follow-up period. At 1 month of
follow-up, the size of the aneurysm increased in two pa-
tients, decreased in 15 patients, and remained the same size
in one patient. On the average, aneurysm size (determined
with computed tomographic scan reading by the same
surgeon) decreased from 68  22 mm to 58  13 mm, to
51  14 mm, and to 49  12 mm at 1, 6, and 12 months
of follow-up, respectively (Fig). This reduction in size was
statistically significant at 6 months (P  .05) and 12
months (P  .01) of follow-up.
In the historic open group, the total perioperative
mortality rate was 10% (1/10). This patient’s postoperative
course was complicated by development of severe adult
respiratory distress syndrome and ischemic colitis. Despite
operative intervention, the patient died on postoperative
day 13. The total morbidity rate in this group was 50%
(5/10), with one minor morbidity (wound infection) and
four major morbidities (severe renal insufficiency, n  2;
stroke with residual hemiparesis, n  1; and ischemic
colitis, n  1). At 1-year follow-up, seven of 10 patients
were alive. One patient died of myocardial infarction dur-
ing the first postoperative year. Another died of unknown
causes.
Spinal drainage was not used in any of the patients in
the endovascular group. No case of spinal cord ischemia
was seen in the endovascular or historic open groups.
DISCUSSION
The incidence rate of TAA has been reported to be
about 10.4 per 100,000 person years.10 Over all, the 5-year
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survival rate improved to 56% between 1980 and 1994,10
compared with only 19% between 1951 and 1980.11 Left
untreated, these aneurysms continue to expand and even-
tually rupture in 16% to 31% of cases over 5 years for
aneurysms greater than 4 cm in diameter.10 Elective and
emergent open operative repair mortality rates have more
recently been reported as 8% and 57%, respectively.10 With
these poor prognostic data, treatment is generally recom-
mended in patients who are symptomatic, with aneurysm
size greater than twice the diameter of the normal aorta
immediately adjacent to the aneurysm or with the largest
aneurysm diameter greater than 6 cm.
Standard open surgical repair of TAA has been re-
ported to have 5-year survival rates between 70% and
79%.10 The reported cardiac, pulmonary, and renal mor-
bidity rates of open repair have been significant.10,12
Endovascular exclusion of TAA offers a less invasive
option compared with the standard open repair technique.
Intuitively, the endoluminal repair would be expected to be
associated with decreased morbidity and mortality rates
compared with the standard open procedure.
The operative morbidity and mortality rates in our
short-term follow-up were 26% and 11%, respectively. Al-
though the mortality rate in the endovascular group was
similar to that in the historic nonrandomized open group in
our study (10%), the morbidity rates in the endovascular
group were less severe than those in the open group.
The use of endovascular grafts for the repair of de-
scending TAA is a rapidly developing field with several stent
graft systems being tested. Herein, we report our 95%
deployment success and 89% 30-day technical success rates
with the Excluder thoracic and Talent endoprostheses. No
conversion to open surgical repair was performed. Compli-
cations related to device deployment included access diffi-
culty (n  1) and femoral artery pseudoaneurysm forma-
tion (n  1). Other complications in this series included
external iliac artery dissection and retroperitoneal hema-
toma (n  1) and lymphocele (n  1). Two deaths oc-
curred, one on postoperative day 2 (Talent) and another at
5 months (Excluder) after implantation.
The patients in this series stayed in the hospital an
average of 6.2 days, with only 47% needing time in the
intensive care unit (range, 1 to 3 days; median, 2 days),
whereas 100% of those in the historic open group needed
intensive care (range, 3 to 44 days). In the endograft group,
the first nine patients were admitted to the intensive care
unit immediately after surgery. The last 10 patients treated
endoluminally were admitted to surgical floor immediately
after surgery.
Spinal cord ischemia was not noted in our series of
patients. Only three of 19 had undergone prior repair of
infrarenal abdmoinal aortic aneurysm. The average aortic
coverage length in our series was 77 mm (range, 10 to 250
mm). Recent reports have identified several factors as the
possible risk factors for spinal cord ischemia. These risk
factors include perioperative hypotension, prior history of
infrarenal abdominal aortic aneurysm repair (compromis-
ing the lumbar spinal arterial collaterals), and long segment
coverage of the thoracic aorta compromising the artery of
Adamkiewicz and the intercostal collaterals to the spinal
arterial supply.5,13
Spinal cord protection maneuvers (spinal fluid drain-
age) were not used in our patients in the endograft group.
All the patients in the historic open group had spinal fluid
drainage catheters placed before surgery. The reported
incidence rate of spinal cord ischemia with these adjunctive
spinal cord protective maneuvers in endovascular patients
has been reported to be 3.3%5 to 5.7%.13 Increased risk is
seen with the use of multiple components covering long
segments of aorta. The combination of distal perfusion and
spinal fluid drainage may optimize spinal cord protection in
the repair of TAA.14,15
The Excluder and Talent endoprostheses are fully sup-
ported stent grafts that may minimize kinking and twisting
during deployment or with aneurysm remodeling by pro-
viding longitudinal support. The risk and incidence of
endoleak at the connections between separate components
are not known. Does this risk increase with the more liberal
use of multiple components? Will the components move in
relation to each other as the aneurysm remodels? How
durable are the metallic and fabric components of these
devices? How do the bench models of cyclic loading and
durability correlate with in vivo outcomes? These impor-
tant questions will only be answered through longer fol-
low-up.
Currently, both the Talent and Excluder thoracic en-
dograft trials have been placed on hold because of identifi-
cation of stent and longitudinal bar fractures in up to 30 %
of the implanted cases. Further work on redesign of these
devices is underway. We believe that these devices will
undergo the same evolutionary change that some of the
infrarenal devices have undergone and after appropriate
testing will be reintroduced for continued clinical evalua-
tion. We further believe that miniaturization of the devices
is secondary to long-term durability in these devices.
A limitation of this study is that the endograft group
represents a highly selective group of patients that was not
randomized with intentional bias towards treatment of
patients with less serious comorbid conditions. The open
group represents a retrospective, nonrandomized, and
small sample size. Follow-up periods for both groups have
been short (12 months). In addition, absence of autopsy
Aneurysm size reduction (mm) during 12-month follow-up pe-
riod. *Statistically significant reduction in diameter of aneurysm.
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information in patients who died in each group complicates
the interpretation of the data. Nevertheless, in this report,
all deaths have been included as treatment failures.
CONCLUSION
We found the treatment of descending TAA with the
Excluder thoracic and Talent endoprostheses to be feasible
and safe in this short-term study. Valuable attributes of-
fered by these devices are a wide variety of component sizes,
availability of more than one component for each case, and
relative ease of deployment. Creation of a user-friendly
system is fundamentally important, provided durability and
accuracy of deployment are not compromised. The signif-
icant reductions in intraoperative blood loss, operative
time, and hospital and intensive care unit stays in the
endograft group, compared with those of the historic open
group, support the use of this device. At 1-year follow-up,
significant reduction was seen in aneurysm size. No cases of
early or late endoleaks, rupture, graft migration, or spinal
cord ischemia were seen. Long-term data on the durability
of these devices and on complete cost analysis will be
necessary for a complete and definitive evaluation.
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